Mirum Pharmaceuticals (MIRM) PT Raised to $156 at Stifel on Clinical/Regulatory Wins

October 15, 2026 9:34 AM

Stifel analyst James Condulis raised the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $156.00 (from $136.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found